PannTheraPi

Panntherapi is a clinical stage biotech company developing innovative drugs in Neurology by acting on a new specific target involved in pathological mechanisms for a higher efficacy and a better safety.

Our 1st in class product is indicated for an orphan epileptic syndrome mostly paediatric and is ready to perform its Phase 2 trial in patients (Phase 1 done, dev. plan validated, 2 patents).

With our unique platform (AI, invitro models, post operative brain tissues from patients), we identified New Chemical Entities (1 patent) to be developed in other diseases of interest: multiple sclerosis, pain, neurodegenerative and psychiatric disorders.

Laureate of the EIC accelerator (grant + equity), of the i-Lab and other awards of excellence, Panntherapi is managed by an experimented team and supported by international experts.